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Background
We reported 10 cases where SCIg turned out to be the
preferred route of Ig replacement therapy for patients who
developed secondary hypogammaglobulinaemia following
bone marrow transplantation or chemotherapy treatment
for neoplasia. Patients’ age ranged from 2 to 19 years old,
7 patients being below the age of 10. Six out of the
10 patients were transitioned from IVIg to SCIg: 4 patients
due to systemic side effects associated to IVIg perfusions
and 2 patients due to poor quality of life related to fre-
quent travels to the hospital for IVIg infusion. Four out of
the 10 patients were Ig naïve patients and were started
directly on SCIg. All patients received a weekly dose of
100mg/Kg infused in two different sites assisted by a bat-
tery-powered pump. Patients were given a 1:1 dose when
transitioned from IVIg to SCIg. A significant increase of
the IgG level was noted in all patients. All patients toler-
ated very well SCIg therapy with no reported systemic
adverse reactions. Local infusion sites reactions were the
most frequent observed reactions with a frequency similar
to the one observed in patients with primary immunodefi-
ciency disorders (PIDD). Lastly, parents reported improve-
ment in quality of life under SCIg therapy; their child had
improved social functioning, better resistance against
infections and much improved overall health.
Conclusion
While home-based SCIg administration relative to hospi-
tal-based IVIg has been shown to improve PIDD patients’
quality of life, we believe that SCIg has the potential to
improve patient’s satisfaction and independence also in
patients with secondary hypogammaglobulinemia.
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